February 12, 2016—Amgen, the world’s largest biotechnology company by revenue, is giving 340B covered entities refunds stemming from “an adjustment of its 340B ceiling price” on nine of its 16 products, including its blockbusters Enbrel, Neulasta, and Prolia. [ms-protect-content id=”2799″]
The Health Resources and Services Administration posted a notice from Amgen about the refunds on the Office of Pharmacy Affairs website late this afternoon. In addition to Neulasta, the company is providing refunds on certain NDCs of
- Aranesp
- Enbrel
- Epogen
- Neupogen
- NPlate
- Prolia
- Sensipar
- Vectibix
For Epogen, Neulasta, Neupogen, NPlate, Prolia, Sensipar, and Vectibix, the refunds are for sales from Q1 2011 through Q1 2015. For Aranesp and Enbrel, the refunds are for sales from Q4 2006 through Q1 2015.
“340B covered entities that purchased the Amgen products…during this timeframe will receive a credit effectuated by Apexus, LLC within the next three to four months, as well as a letter about the change in price,” Amgen’s letter on the OPA website says. “Any questions should be directed to 340BRelations@amgen.com.” The letter does not explain why Amgen is adjusting its 340B ceiling prices for the drugs. [/ms-protect-content]